ULK2 Inhibitors

ULK2 inhibitors constitute a diverse array of compounds that intricately regulate autophagy by directly or indirectly modulating ULK2, a pivotal protein in the initiation of this cellular process. Among the direct inhibitors, SBI-0206965 and MRT68921 stand out as they selectively target ULK2's kinase domain, impeding its enzymatic activity and disrupting the formation of autophagosomes. These compounds represent a crucial class of ULK2 inhibitors with a specific molecular mechanism. In contrast, indirect ULK2 inhibitors include MHY1485 and Spautin-1, each influencing autophagy through distinct pathways. MHY1485 impacts mTOR, while Spautin-1 targets the ubiquitin-proteasome pathway. These compounds showcase the intricate web of cellular processes that converge on ULK2, highlighting the complexity of autophagy regulation. Dorsomorphin, an AMPK inhibitor, and CC-115, a dual mTOR/DNA-PK inhibitor, indirectly affect ULK2 by altering energy-sensing pathways, resulting in a reduction of autophagy. This dual approach to ULK2 modulation demonstrates the multifaceted nature of autophagy regulation within the cell.

Additionally, inhibitors like 3-Methyladenine (3-MA) and LY-294002, targeting PI3-kinase, disrupt the activation of the ULK complex, impeding the early stages of autophagosome formation. PF-4708671, another AMPK inhibitor, contributes to the modulation of cellular energy status, indirectly affecting ULK2 and influencing autophagy regulation. The diversity in these compounds emphasizes the intricate interplay of signaling pathways involved in the finely tuned control of autophagy. Moreover, compound classes such as dual ULK1/2 inhibitors (e.g., MRT67307) and GSK-3 inhibitors (e.g., SB216763) provide versatile options for targeting ULK2. MRT67307 directly binds to ULK1/2 kinases, while SB216763 modulates the Wnt signaling pathway, indirectly impacting ULK2.